BioSpace News Archive

The decision comes after the Phase II MOONSONG trial on the oral antiviral pill AT-527 failed to meet the primary endpoint in October.

Seasonal Affective Disorder more than winter blues, and there are steps to take to prevent it or combat the sadness and lack of energy. Know more about it here.

Finding a job in the pharmaceutical industry can be challenging. Find out which skills can help you score your dream pharmaceutical company job.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a strategic partnership with Merck KGaA, Darmstadt, Germany, in companion diagnostics (CDx) development for the MET inhibitor tepotinib in the mainland China market.

Certara, Inc., a global leader in biosimulation, announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders at a price to the public of $31.00 per share.

According to a new market report published by Transparency Market Research “Scar Treatment Market, By treatment type ), Laser Treatment, Injectables, Others, By Distribution Channel – Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2019 – 2027”.

Nicox SA, an international ophthalmology company, announced that patent EP 3,769,753, expiring in 2040 and covering the Company’s product candidate in development for blepharitis, NCX 4251, has been issued by the European Patent Office.

TMR observes that the global transdermal scopolamine market is experiencing the high competition and consolidation due to presence of strong players. Some of the key players operating in the global transdermal scopolamine market includes Baxter International Inc., Novartis AG, GlaxoSmithKline Plc, Caleb Pharmaceuticals Inc, Perrigo Co.

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported a second case of a patient with late-stage retinitis pigmentosa who partially recovered her visual function after treatment with GS030 optogenetic therapy.

BioAgilytix, a leading global contract research organization, announced an agreement to be further capitalized by Cinven, a leading international private investment firm focused on building world-class global companies.